New advances in antiretroviral therapy

R. Chris Rathbun, Johnny Stephens, Jeffrey Stroup

Research output: Contribution to journalReview article

Abstract

Antiretroviral drug resistance and adverse events represent ongoing challenges in the management of HIV infection. The introduction of the integrase inhibitor raltegravir, the chemokine receptor antagonist maraviroc, the nonnucleoside reverse transcriptase inhibitor (NNRTI) etravirine, and the protease inhibitor (PI) darunavir represent important advances in the treatment of patients who have HIV/ AIDS and extensive drug resistance or intolerance. Raltegravir has been shown to be as effective as efavirenz with the advantage of a better adverse-effect profile. Maraviroc has been shown to be effective - in combination therapy - for (early-stage) CCR5-tropic HIV-1 infection in adults with resistance to multiple agents. Etravirine is designed to circumvent resistance to NNRTIs caused by certain viral mutations. Darunavir, like other PIs, prevents maturation of new virus particles. The pharmacokinetics, clinical evidence on efficacy, resistance, dosing, and adverse effects of these new agents are discussed in this article.

Original languageEnglish
Pages (from-to)113-120
Number of pages8
JournalInfections in Medicine
Volume26
Issue number4
StatePublished - 1 Apr 2009

Fingerprint

etravirine
efavirenz
Drug Resistance
HIV Infections
Integrase Inhibitors
Anti-HIV Agents
Reverse Transcriptase Inhibitors
Chemokine Receptors
Protease Inhibitors
Virion
HIV-1
Pharmacokinetics
HIV
Mutation
Therapeutics
maraviroc
Raltegravir Potassium
Darunavir

Keywords

  • Antiretrovirals
  • CCR5 antagonists
  • Integrase inhibitors
  • Nonnucleoside reverse transcriptase inhibitors
  • Protease inhibitors

Cite this

@article{5cf8fb65a38545b68bcff9b4825d3480,
title = "New advances in antiretroviral therapy",
abstract = "Antiretroviral drug resistance and adverse events represent ongoing challenges in the management of HIV infection. The introduction of the integrase inhibitor raltegravir, the chemokine receptor antagonist maraviroc, the nonnucleoside reverse transcriptase inhibitor (NNRTI) etravirine, and the protease inhibitor (PI) darunavir represent important advances in the treatment of patients who have HIV/ AIDS and extensive drug resistance or intolerance. Raltegravir has been shown to be as effective as efavirenz with the advantage of a better adverse-effect profile. Maraviroc has been shown to be effective - in combination therapy - for (early-stage) CCR5-tropic HIV-1 infection in adults with resistance to multiple agents. Etravirine is designed to circumvent resistance to NNRTIs caused by certain viral mutations. Darunavir, like other PIs, prevents maturation of new virus particles. The pharmacokinetics, clinical evidence on efficacy, resistance, dosing, and adverse effects of these new agents are discussed in this article.",
keywords = "Antiretrovirals, CCR5 antagonists, Integrase inhibitors, Nonnucleoside reverse transcriptase inhibitors, Protease inhibitors",
author = "Rathbun, {R. Chris} and Johnny Stephens and Jeffrey Stroup",
year = "2009",
month = "4",
day = "1",
language = "English",
volume = "26",
pages = "113--120",
journal = "Infections in Medicine",
issn = "0749-6524",
publisher = "CMP Healthcare Media LLC",
number = "4",

}

New advances in antiretroviral therapy. / Rathbun, R. Chris; Stephens, Johnny; Stroup, Jeffrey.

In: Infections in Medicine, Vol. 26, No. 4, 01.04.2009, p. 113-120.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New advances in antiretroviral therapy

AU - Rathbun, R. Chris

AU - Stephens, Johnny

AU - Stroup, Jeffrey

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Antiretroviral drug resistance and adverse events represent ongoing challenges in the management of HIV infection. The introduction of the integrase inhibitor raltegravir, the chemokine receptor antagonist maraviroc, the nonnucleoside reverse transcriptase inhibitor (NNRTI) etravirine, and the protease inhibitor (PI) darunavir represent important advances in the treatment of patients who have HIV/ AIDS and extensive drug resistance or intolerance. Raltegravir has been shown to be as effective as efavirenz with the advantage of a better adverse-effect profile. Maraviroc has been shown to be effective - in combination therapy - for (early-stage) CCR5-tropic HIV-1 infection in adults with resistance to multiple agents. Etravirine is designed to circumvent resistance to NNRTIs caused by certain viral mutations. Darunavir, like other PIs, prevents maturation of new virus particles. The pharmacokinetics, clinical evidence on efficacy, resistance, dosing, and adverse effects of these new agents are discussed in this article.

AB - Antiretroviral drug resistance and adverse events represent ongoing challenges in the management of HIV infection. The introduction of the integrase inhibitor raltegravir, the chemokine receptor antagonist maraviroc, the nonnucleoside reverse transcriptase inhibitor (NNRTI) etravirine, and the protease inhibitor (PI) darunavir represent important advances in the treatment of patients who have HIV/ AIDS and extensive drug resistance or intolerance. Raltegravir has been shown to be as effective as efavirenz with the advantage of a better adverse-effect profile. Maraviroc has been shown to be effective - in combination therapy - for (early-stage) CCR5-tropic HIV-1 infection in adults with resistance to multiple agents. Etravirine is designed to circumvent resistance to NNRTIs caused by certain viral mutations. Darunavir, like other PIs, prevents maturation of new virus particles. The pharmacokinetics, clinical evidence on efficacy, resistance, dosing, and adverse effects of these new agents are discussed in this article.

KW - Antiretrovirals

KW - CCR5 antagonists

KW - Integrase inhibitors

KW - Nonnucleoside reverse transcriptase inhibitors

KW - Protease inhibitors

UR - http://www.scopus.com/inward/record.url?scp=69249158672&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:69249158672

VL - 26

SP - 113

EP - 120

JO - Infections in Medicine

JF - Infections in Medicine

SN - 0749-6524

IS - 4

ER -